Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells  by Perego, Michela et al.
Heterogeneous Phenotype of Human Melanoma Cells
with In Vitro and In Vivo Features of Tumor-Initiating
Cells
Michela Perego1, Monica Tortoreto1, Gabrina Tragni2, Luigi Mariani3, Paola Deho1, Antonino Carbone2,
Mario Santinami4, Roberto Patuzzo4, Pamela Della Mina5, Antonello Villa5, Graziella Pratesi1, Giacomo
Cossa1, Paola Perego1, Maria G. Daidone1, Malcolm R. Alison6, Giorgio Parmiani1,7, Licia Rivoltini1 and
Chiara Castelli1
Melanospheres, the melanoma cells that grow as nonadherent colonies and that show in vitro self-renewing
capacity and multipotency, were selected from melanoma specimens or from melanoma cell lines. Melano-
spheres were highly tumorigenic, and intradermal injections in severe combined immunodeficient (SCID) mice
of as few as 100 cells generated tumors that maintained tumorigenic potential into subsequent recipients.
Primary and serially transplanted xenografts recapitulated the phenotypic features of the original melanoma of
the patient. Melanoma cells cultured in the presence of fetal calf serum (FCS) were also tumorigenic in SCID
mice, although with lower efficiency; these xenografts showed a homogeneous phenotype for the expression of
melanoma-associated markers, Melan-A/Mart-1, HMB45, and MITF, and contained cells with features of fully
differentiated cells. Melanospheres were heterogeneous for the expression of stem cell markers and showed a
significantly enhanced expression of the Nanog and Oct3/4 transcription factors when compared with adherent
melanoma cells. No direct and unique correlation between any of the examined stem cell markers and in vivo
tumorigenicity was found. Taken together, our data provide further evidence on the heterogeneous nature of
human melanomas and show that melanospheres and their corresponding tumors, which are generated in vivo
in immunocompromised mice, represent a model to investigate melanoma biology.
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INTRODUCTION
The cancer stem cell theory proposes that tumors can be
viewed as the result of an anomalous differentiation program
of putative cancer stem cells (CSCs). Although probably
representing a minor population of the whole tumor mass,
CSCs are believed to constitute a unique cell subset
responsible for tumor maintenance and growth (Reya et al.,
2001; Lee and Herlyn, 2007; Ailles and Weissman, 2007).
However, the parent-to-progeny relationship between CSCs
and the tumor bulk population does not necessarily reflect
the well-conserved and predictable rules operating in normal
tissue organization. Instead, because of the intrinsic genetic
and epigenetic instability of cancer cells, it is more likely that
tumor generation represents an aberrant and highly unstable
differentiation program (Adams and Strasser, 2008; Odoux
et al., 2008). Moreover, recent data suggest that tumor
heterogeneity can result from variability in the frequency,
phenotype, and functional features of CSCs (Piccirillo et al.,
2009).
Although there is no definitive consensus on the pheno-
type and frequency of CSCs in the majority of human tumors,
much experimental evidence supports the contentions that
many tumors of both epithelial and nonepithelial origin have
operationally defined CSCs (cells able to propagate tumors in
immunodeficient mice) and that the presence of these CSCs
affects tumor biology (Alison et al., 2008; Dick, 2009; Jordan,
2009).
Melanoma, one of the most aggressive human cancers
with metastatic lesions resistant to conventional therapies, is
highly heterogeneous and shows a high degree of plasticity
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(Hendrix et al., 2003; Mourad-Zeidan et al., 2008). Recent
evidence indicates that human melanomas contain different
cell populations endowed with intrinsic chemoresistance
(Frank et al., 2005). Moreover, it has been shown that stem-
associated markers such as CD133, CD166, and nestin are
expressed by human melanomas (Klein et al., 2007).
Although the nature and frequency of CSCs in melanoma is
controversial, it is likely that the CSC model can be applied to
human melanoma, and different surface markers have been
proposed to define melanoma cells with tumor-initiating
potential (Fang et al., 2005; Monzani et al., 2007; Keshet
et al., 2008; Schatton et al., 2008). A recent study using
nonobese diabetic/severe combined immunodeficient (SCID)
Il2rg/ mice for an in vivo assay of tumor initiation
suggested a very high frequency of CSCs in melanoma;
moreover, an analysis of a large panel of melanoma-related
markers failed to find any correlation between a specific
phenotype and tumor-initiating capacity in vivo (Quintana
et al., 2008). Thus, stem cells in melanoma are worthy of
investigation, and our study evaluated the presence of cells
showing in vitro and in vivo features of tumor-initiating cells
in human metastatic melanomas.
RESULTS
Anchorage-independent, self-renewing melanospheres variably
express stem-associated markers
Stem cell medium (SCM) supported the selection of cells
growing as melanospheres in 8 of the 18 lymph node
melanoma metastases used in this study (44% success rate). A
similar percentage of melanosphere formation (32%) was
achieved by starting from melanoma cell lines previously
established as adherent cells in medium supplemented with
fetal calf serum (FCS). MeJR8S and Me204S, derived from the
adherent melanoma cell lines, and Me15888S and
Me14346S, derived directly from lymph node metastasis,
were used throughout this study. The self-renewing capacity
of tumor spheres was assayed by sphere formation and
clonogenic assays. Both tests gave consistent results, showing
that all of the melanospheres showed a higher frequency of
self-renewing cells than adherent melanomas (Table 1).
Melanospheres were cultured in differentiating media for
cells of the mesenchymal lineage: chondrocytes, osteocytes,
and adipocytes. Me204S was able to differentiate into all
three cell types with similar efficiencies (Supplementary
Figure S1 online). Melan-A/MART-1 expression, a marker of
melanocyte differentiation, was evaluated after growing
melanosphere-derived cells in the presence of 10% FCS.
The corresponding adherent melanoma cell line Me204ADH
did not show differentiation capability and maintained a high
expression of Melan-A/MART-1. Similar differentiation rates
were obtained for MeJR8S, Me15888S, and Me14346S (data
not shown).
All of the generated melanospheres were negative for the
hematopoietic marker CD45. Conversely, all of them were
100% positive for Melan-A/MART-1 and HMB45 melanocyte
differentiation proteins (Figure 1a). The expression of CD146
and GD3 was variable, with virtually all Me14346S cells
staining negative for GD3 and a very low percentage staining
positive for CD146 (Figure 1a). Melanosphere cells also
expressed several embryonic stem cell markers, and all four
of the melanosphere lines were almost 100% positive for
CD9, SOX2 Oct3/4, and Nanog proteins whereas a very low
percentage of cells (or none at all) expressed SSEA-1 and
SSEA-4. A low rate of expression was observed for Musashi-1,
with 13–16% of Me15888S and Me204S cells staining
positive (Figure 1b and Supplementary Figure S2 online).
The expression of stem-related markers used to identify adult
stem cells of normal and malignant tissue (CD20, CD24,
CD44, CD73, CD133, CD166, nerve growth factor receptor
(NGFR), and nestin) was examined (O’Brien et al., 2009).
NGFR and nestin were included because of their expression
in cells of the neural crest (Lee et al., 2007). All the
melanosphere lines were negative for CD20 and positive for
CD44 and nestin. Conversely, CD24, CD73, CD166, NGFR,
and CD133 markers were expressed in different percentages
of cells in all the melanosphere lines. In Me15888S, a
majority of cells were CD133, CD166, and CD73þ , and
this melanosphere line had the highest percentage of NGFR-
positive cells (Figure 1c).
The expression of all the above markers was also assessed
in Me204ADH, JR8ADH, and Me14346ADH and in seven
additional pairs of adherent and melanosphere melanoma
lines. Among the examined markers, only the expression of
the stem-related proteins Nanog and Oct4 was significantly
Table 1. Self-renewal of melanospheres (S) and
melanoma-adherent cells (ADH)
% of melanospheres
Cell type SFA1 Clonogenic assay2
Me204
S 54±7.153 52.7±5.6
ADH 10.7±8.2 4.4±0.3
MeJR8
S 25.6±1.1 18.5±2.1
ADH 8.2±3.8 6.4±0.2
Me14346
S 26.9±4.1 11.8±4.2
ADH 0.9±1.1 0
Me158884
S 14±8.2 5.8±1.8
Abbreviation: SFA, Sphere Formation Assay.
1Percentage of melanospheres per 100 cells.
2Percentage of clones per total single cells seeded.
3Mean±SD calculated on the bases of three independent experiments.
4Fresh melanoma cell suspension derived from lymph node melanoma
metastasis no. 15888 failed to establish an adherent melanoma cell line,
and thus the adherent counterpart of Me15888S is not available for
analysis.
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Figure 1. Immunophenotype of melanospheres. Immunofluorescence and FACS analysis of CD45 and melanoma-associated markers. Shown are the
(a) embryonic, (b) adult, and (c) stem cell markers expressed by melanospheres generated from melanoma cell lines (Me204S and JR8S) and from fresh
melanoma specimens (Me15888S and Me14346S). Thin black histograms represent controls stained with negative isotopic antibodies; filled histograms
correspond to specific markers; numbers indicate the percentage of positive cells. Histograms are representative of three independent experiments.
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enhanced in melanospheres when compared with adherent
cells, and only CD146 was significantly downregulated
(Figure 2).
Real-time PCR clearly showed that ABCB1, ABCB5, and
ABCG2 genes were expressed by melanocytes. Moreover, all
of the melanosphere and adherent cell lines were positive for
ABCG2, whereas they variably expressed ABCB1 and ABCB5
(Supplementary Table S1 online).
Melanospheres are endowed with enhanced tumorigenicity
when compared with adherent melanoma cells
The tumorigenicity of melanospheres was assessed by
evaluating their capacity to form melanomas when intrader-
mally injected into SCID mice. At a dose of 104 cells, all of
the melanosphere lines generated fast-growing tumors in
100% of injected mice within 14–48 days. Notably, all of the
melanosphere lines could form tumors when as few as 100
cells were injected per mouse, and two of them (Me15888S
and MeJR8S) formed tumors in 100% of mice even at this
low dose. Primary xenografts were then serially transplanted
into subsequent animal hosts. Secondary and tertiary
tumors developed in 100% of injected mice; interestingly,
serial tumors grew as fast or faster than their corresponding
primary engraftment (Table 2 and Supplementary Figure S3
online).
To provide evidence that the melanoma xenografts
generated by melanospheres may have had a clonal origin,
SCID mice were inoculated with escalating doses of cells
derived from melanospheres generated from a single mela-
noma clone, P1E8S. Tumor take, latency, and secondary
tumor formation were all similar to those of the parental
melanosphere bulk population (JR8S) from which the clone
was generated (Supplementary Table S2 online).
Because melanospheres endowed with strong tumorigenic
potential could have been selected from melanoma cells
adapted to grow in FCS, and because even the adherent
melanoma lines had a limited but detectable in vitro
self-renewal capacity, Me204ADH, MeJR8ADH, and
Me14346ADH cells were inoculated in SCID mice to
evaluate the extent to which they possess tumor-initiating
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Figure 2. Oct3/4, Nanog, and CD146 are modulated in melanospheres when compared with adherent cells. The left column shows the box-and-whisker
plots for the markers that were differentially expressed in melanospheres when compared with adherent cells. The fluorescence intensity (X mean) on the y axis
equals the X mean (marker) minus the X mean (isotype control). Values are calculated as the mean of three independent experiments. Histograms of the
differential expression of Oct3/4, Nanog, and CD146 in Me204S (black) and Me204ADH (gray) are reported. Lines and filled histograms correspond to isotype
controls and specific antibodies, respectively (P-values evaluated with unpaired t-test). In all, 11 melanoma adherent cell lines and 11 melanospheres
were analyzed.
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capacity in vivo. As expected, tumor take decreased with
diminishing numbers of injected cells; the efficiency of
primary tumor formation was lower when compared with
that of the corresponding melanospheres, and the latency of
tumor formation was longer (Table 2). Moreover, once
established, the primary tumors generated by the adherent
melanoma lines grew slower than the tumors generated by
the corresponding melanosphere lines (Supplementary Table
S3 online).
These quantitative differences in the in vivo behavior of
melanospheres and adherent melanoma cells were assessed
by statistical analysis. The log-normal regression model
yielded highly significant results for treatment (adherent vs.
melanosphere cells; Po0.0001), thus confirming the higher
tumorigenic potential of melanospheres when compared with
adherent melanoma cells. Statistically significant results were
also obtained for cell line (Po0.0001) and dose (Po0.0001),
indicating that both factors affected tumorigenicity. Con-
versely, the interactions between treatment and cell line
(P¼0.22) or inoculating dose (P¼ 0.30) were not significant,
indicating that melanospheres have a higher tumorigenic
potential than adherent melanoma cells, independent of cell
line and dose. Tumor mass was significantly affected by
treatment (adherent vs. melanosphere cells; P¼ 0.0045) but
not by cell line (P¼0.16) or dose (P¼ 0.35), and no
significant interactions between treatment and cell line
(P¼0.29) or treatment and dose (P¼0.79) were found.
These analyses support the conclusion that, once established,
tumors generated by melanospheres grow more aggressively,
and that this aggressive behavior is a function of their
melanosphere origin.
Primary tumors derived from adherent cells were serially
transplanted in additional recipients. Differences in translat-
ability, evaluated as tumor take, between adherent and
melanosphere-derived primary xenografts emerged in tertiary
tumor formation with Me204ADH- and Me14346ADH-
derived tumors failing to grow. Me14346ADH xenografts
showed very poor viability (Table 2), and viable tumor cells
were only obtained from tumors generated by the injection of
106 melanoma cells. However, at the same cell dose, no
serial engraftment was successfully established. Of note and
at difference from Me204ADH and Me14346ADH, MeJ
R8ADH showed transplantation efficiency equal to its
autologous MeJR8S, and 100% tumor take occurred with
all four tumors growing in tertiary recipients.
Xenografts generated by melanospheres recapitulate the
phenotypic features of the original human melanoma
Histological evaluation confirmed that human melanoma
xenografts generated in SCID mice by melanospheres
consisted of cells showing the typical morphology of
melanoma cells: eosinophilic cytoplasm, irregular nuclei,
and prominent nucleoli. Xenografted tumors expressed the
specific melanoma markers HMB45, Melan-A/Mart-1, and
MITF-1. Moreover, although melanospheres were homoge-
neously positive for Melan-A/MART-1, this marker was
heterogeneously expressed in the growing tumor mass; i.e.,
Melan-A/Mart-1-negative melanoma cells could be found.
In general, this heterogeneity, as well as the levels of
MITF and HMB45, mirrored that of the patient’s original
tumor (Figure 3a). Furthermore, the similarity between the
Table 2. In vivo tumorigenicity of melanosphere-
forming cells (S) and adherent melanoma cells (ADH)
Primary
tumor formation
Secondary
tumor formation
Tertiary
tumor formation
Cell
type
Cell
number1 Take2 Latency3 Take2 Latency3 Take2 Latency3
MeJR8
S 104 5/5 22 2/2 25 2/2 18
103 5/5 29 ND ND ND ND
102 5/5 22 ND ND 2/2 35
ADH 104 5/5 22 2/2 25 2/2 30
103 4/5 49 ND ND
102 3/5 49 ND ND 2/2 50
Me204
S 104 4/4 14 2/2 36 2/2 28
103 5/5 22 ND ND ND ND
102 2/5 39 ND ND ND ND
ADH 105 ND ND 2/2 36 0/2 ND
104 5/5 25 2/2 60 0/2 ND
103 5/5 67 ND ND ND ND
102 0/5 ND ND ND ND ND
Me14346
S 104 5/5 48 2/2 30 ND ND
103 4/5 92 3/3 40 2/2 30
102 3/5 123 3/3 40 3/3 40
5 101 ND ND ND ND 3/3 57
ADH 106 2/2 19 0/14 ND ND ND
104 5/5 77 0/24 ND ND ND
103 4/5 77 ND ND ND ND
102 3/5 123 0/24 ND ND ND
Me158885
S 104 5/5 33 3/3 35 3/3 35
103 5/5 33 ND ND ND ND
102 5/5 53 ND ND ND ND
Abbreviation: ND, not done.
1Number of injected cells.
2Number of tumors formed per number of injections.
3Time from injection to tumor measurability. Median values are reported.
Observation time is 200 days.
4Observation time is 60 days.
5Fresh melanoma cell suspension derived from lymph node melanoma
metastasis no. 15888 failed to establish an adherent melanoma cell line,
and thus the adherent counterpart of Me15888S is not available for
analysis.
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Figure 3. Melanospheres are tumorigenic and reproduce humanmelanoma in immunocompromised mice. Immunohistological staining of (a) melanoma-associated
and (b) stem-related markers in xenograft tumors generated by intradermal injection of melanosphere-derived cells and in lymph node metastatic melanomas of
patient 204 and patient 15888. Internal scale markers are indicated in each panel. For melanosphere-derived xenografts, reported images are representative of eight
independently analyzed xenografts; for patients’ tumors, images are representative of two non-consecutive tumor sections. Scale bar¼100mm.
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melanosphere-derived tumors and the patient’s original
tumor was also maintained with regard to the expression of
the stem-related markers CD133, CD166, NGFR, and nestin
(Figure 3b).
The stem-related markers showed an elevated degree of
variability in expression, with CD166 and nestin expressed
by the majority of cells in the tumor mass, and CD133
expressed by very few tumor cells. This distribution was
confirmed by the analysis of 10 primary melanoma lesions
and their paired metastases (Supplementary Table S4 and
Figure S4 online).
Conversely, immunohistochemistry showed that adherent
cell-derived xenografts uniformly expressed the differentia-
tion markers, Melan-A/MART-1 and HMB45, and had an
elevated level of the transcription factor MITF when
compared with the melanosphere-derived tumors and the
patient’s original tumor (Figure 4a). These xenografts were
also heavily pigmented, as shown by melanin-specific
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Figure 4. Immunohistochemistry and ultrastructural analysis of xenografted tumors. Immunohistochemical staining of (a) melanoma-associated and
(b) stem-related markers was performed on xenografts generated by intradermal injection of adherent melanoma cells Me204 and MeJR8. For each cell line,
reported images are representative of eight independently analyzed xenografts. Internal scale markers are indicated in each panel. (c) Melanin staining
and transmission electron microscopy (TEM) analysis. Fontana-Masson melanin-specific staining (c, left panels) and TEM (c, middle and right panels) on
melanoma xenografts derived from the injection of Me204 melanospheres (upper panels) or Me204-adherent cells (lower panels). M, melanosomes;
Mt, mitochondria; N, nucleus. Scale bar¼ 100mm. For TEM, left panel scale bar¼2 mm and right panel scale bar¼500 nm.
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staining (Figure 4c, left panel). High numbers of melano-
somes, mostly in their terminal differentiation phase, were
detected by electron microscopy in these adherent cell-
derived tumors, whereas only a few, mainly immature
melanosomes, were found in melanosphere-derived tumors
(Figure 4c, right panel).
DISCUSSION
In this study we show that from lymph node metastatic
lesions we isolated, by selective in vitro culture,
melanoma cells growing as melanospheres, which had
distinctive features of melanomas such as the expression
of Melan-A/Mart-1 and HMB45 and that showed
in vitro self-renewing capacity, multipotency, and strong
tumorigenic potential in immunocompromised mice.
Moreover, the human melanoma xenografts, generated in
immunocompromised mice by the injection of melano-
spheres, recapitulated the original heterogeneity of the
patient’s tumors.
Our data show that melanospheres can be selected
with high efficiency from bulk melanoma cells and
from established adherent melanoma cell lines, and that
these cells show a high clonogenicity and a strong in vivo
tumorigenicity, suggesting a high frequency of cells endowed
with or acquiring tumorigenic potential once injected in vivo.
All the melanoma samples that we studied were derived
from lymph nodes or visceral metastasis and it is conceivable
that metastases may be naturally enriched with regard to
tumorigenic cells (Croker and Allan, 2008; Chiang and
Massague, 2008); in fact, cells undergoing an epithelial–
mesenchymal transition and acquiring the ability to invade
and metastasize are also endowed with tumorigenic
properties (Mani et al., 2008; Gupta et al., 2009). It is
tempting to speculate that metastases could be particularly
enriched for tumorigenic cells and, because it is known that
melanomas are generally highly metastatic and endowed
with a high degree of plasticity (Hendrix et al., 2003;
Mourad-Zeidan et al., 2008), this theory could explain
the high frequency of tumorigenic cells in this particular
human cancer.
The melanosphere phenotype confirmed their melanocy-
tic origin, was heterogeneous with regard to stem-associated
markers, and tumorigenicity was not linked with any
particular phenotypic profile. Recently, studies have stressed
the role of CD133 as a cancer stem cell marker in a set of
human solid tumors, including melanoma (Monzani et al.,
2007; O’Brien et al., 2007). In this study we show that
melanospheres homogeneously expressing CD133 were
endowed with the same tumorigenicity as melanospheres
with only a limited percentage of CD133þ cells. Similarly,
we did not detect any specific enrichment of CD20þ cells in
melanospheres. These data parallel the complexity of
characterizing CSC markers, and currently no definitive
consensus has been reached on the CSC phenotype for
melanoma (Fang et al., 2005; Frank et al., 2005; Monzani
et al., 2007; Keshet et al., 2008; Schatton et al., 2008;
Quintana et al., 2008) or indeed for other solid tumors or
normal tissues (Dalerba et al., 2007; O’Brien et al., 2007;
Ricci-Vitiani et al., 2007; Becker et al., 2008; Shmelkov et al.,
2008; Cheng et al., 2009; Sun et al., 2009).
The histological features of the xenografts generated by
melanospheres clearly resembled those of human
melanomas, thus recapitulating the original tumor hetero-
geneity. Although the melanospheres were homogenously
positive for Melan-A/MART-1, this marker was heteroge-
neously expressed in melanoma xenografts, and in
general, the expression patterns of melanoma-associated
markers and stem-related markers mirrored those of the
patient’s original tumors. In particular, very few cells
were CD133þ , and scattered NGFRþ cell nests were
detected in the xenografts as well as in the original
human tumors. These patterns of staining were also found
in a panel of primary and metastatic paired melanomas,
confirming that this heterogeneity is a general trait of human
melanomas.
In vitro self-renewal, defined as the ability of the cells to
grow in SCM when seeded at clonogenic density, and the
ability to form tumors in immunocompromised mice
were not only unique features of melanospheres but they
were also detected in adherent melanoma cells. In agreement
with the literature (Rodolfo et al., 1988), we found that
melanoma cells grown as adherent cells in medium contain-
ing FCS also formed tumors in SCID mice. However, the
efficiency of tumor formation was lower for adherent
cells when compared with the corresponding melanospheres,
and the latency of tumor growth was delayed in the
group of tumors derived from adherent melanoma cells. In
agreement with these quantitative differences, xenografts
derived from adherent melanoma cells qualitatively
diverged from xenografts generated by melanospheres and,
in general, adherent cell-derived tumors showed a highly
differentiated phenotype, as evidenced by ultrastructural
analysis.
Of note, we found that the melanoma cell line
MeJR8ADH, derived from visceral metastasis (stage IV
melanoma), showed over serial in vivo passages equal tumor
take to its melanosphere counterpart. These data, together
with the evidence that melanospheres could have been
generated from their corresponding adherent melanoma
cells, strongly suggest that putative melanoma stem cells
are likely contained both among melanospheres and adher-
ent melanoma populations. Nevertheless, because of the
absence of molecular marker(s) or lineage tracing in vivo, our
data did not definitively address the issue of the presence and
relative frequency of CSCs in melanosphere and adherent
melanoma cells.
Taken together, our data add to the existing evidence that
human melanoma is a heterogeneous cancer composed of
cells with different characteristics and suggest that melano-
spheres and their corresponding tumors in immunocompro-
mised mice represent a reliable model to analyze melanoma
biology. A better understanding of the fate of melanospheres
inoculated in vivo, and their response to stimuli deriving from
the tumor stroma, will offer the possibility to better under-
stand the mechanisms driving melanoma formation and
progression.
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MATERIALS AND METHODS
Melanoma cell cultures
Lymph node melanoma metastases were collected upon patients’
informed written consent. The melanoma adherent cell lines
Me204ADH and Me14346ADH were established as reported
(Vallacchi et al., 2008). The melanoma cell line JR8ADH, derived
from a melanoma lung metastasis, was kindly provided by Dott G.
Zuppi, Istituto Regina Elena, Rome. Fresh melanoma cell suspension
derived from lymph node melanoma metastasis no. 15888 failed to
establish an adherent melanoma cell line. To generate Me15888S
and Me14346S melanospheres, fresh melanoma cells were seeded at
clonal density (2,500–5,000 cells cm–2) in 75-cm2 flasks in SCM
consisting of DMEM/F-12 (Lonza, Valais, Switzerland), supplemen-
ted with N2 supplement (Invitrogen, Carlsbad, CA). Melanospheres
Me204S and JR8S were derived by plating melanoma cells grown as
a monolayer (Me204ADH and MeJR8ADH) in SCM. Clone P1E85
was derived by plating primary melanospheres of JR8S at clonal
density (1 cell per well) in SCM. The study was conducted according
to the Declaration of Helsinki Principles.
Sphere formation assay and clonogenic assay
For the sphere formation assay, 100 single, viable melanoma cells
were plated in 500ml of SCM in poly-L-lysine (Sigma, St Louis, MO),
coated overnight in a 48-well plate and melanospheres were counted
after 5–8 days. For the clonogenic assay, 100ml of SCM containing
2.5 cellsml–1 was seeded in 96-well plate. After 2–4hours, wells were
examined under the microscope and wells containing a single cell
were followed for sphere formation over the following days.
Flow cytometry
The primary antibodies, anti-human CD24, CD44, CD73, CD146,
CD166, and NGFR (CD271) were all from Becton Dickinson (Franklin
Lakers, NJ). In addition, anti-human CD133 (clone C293; Miltenyi,
Bergisch Gladback, Germany); anti-human Nestin (R&D, Minneapolis,
MN); anti-human Melanosome (HMB45, Dako, Glostrup, Denmark) and
anti-human Melan-A/MART-1 (clone M2-7; Kawakami et al., 1997); and
anti-human Musashi-1, Sox2, Oct3/4, and Nanog (R&D) were used. For
intracellular staining, Cytofix/Cytoperm and Perm/Wash buffer (Becton
Dickinson) were used; nuclear antigens were analyzed in cells fixed with
4% paraformaldehyde and permeabilized with TX-100 0.1% in
phosphate-buffered saline for 30minutes at room temperature. Data
were acquired by FACScalibur (Becton Dickinson) and analyzed using
FlowJo, V 8.5.2, Tree Star, Ashland, OR.
Real-time PCR
RNA extraction and digestion with DNase were carried out using the
RNAqueous-4PCR Kit (Ambion, Carlsbad, CA). Complementary
DNA synthesis was performed with the High-Capacity complemen-
tary DNA Reverse Transcription Kit (Applied Biosystems, Carlsbad,
CA). The real-time PCR reaction was performed with inventoried
assays, using the ABI 7900HT instrument (Applied Biosystems).
In vivo tumorigenicity
SCID mice, 7 weeks old, were intradermally injected with
melanoma cells, resuspended in phosphate-buffered saline, and
mixed with Matrigel (Becton Dickinson) in a 1:1 ratio (Charles River,
Wilmington, MA). Viability of the injected cells was determined
using the Trypan blue exclusion test. To perform serial engraftments,
mice bearing tumors of approximately 500mg were killed, their
tumors were dissociated, and viable single cells were re-injected into
SCID mice. The experiments were approved by the Ethics
Committee for Animal Experimentation of the Istituto Nazionale
Tumori of Milan, according to the institutional guidelines.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections (1–2 mm) were
stained according to the standard procedures (Vallacchi et al., 2008;
Klein et al., 2007) with the following primary mouse anti-human
antibodies: anti-melanosome, 1:50 (HMB45, Dako); anti-Melan-A,
1:50 (Dako clone A103); anti-MITF, 1:200 (clone 34CA5; Novocas-
tra Laboratories, New Castle, UK); anti-nestin, 1:200 (Chemicon
International, Bilerica, MA); anti-CD166, 1:40 (clone MOG/07;
Novocastra Laboratories); anti-NGFR, 1:50 (Novocastra Labora-
tories); and anti-CD133, 1:25 (clone AC133; Miltenyi). Stained
sections were analyzed by optical microscope (Nikon Eclipse 600,
Nikon, Tokyo, Japan). Fontana-Masson silver staining was performed
on 6-mm deparaffinized and hydrated sections according to the
standard procedures.
Transmission electron microscopy analysis
Tumors were fixed with 4% paraformaldehyde and 2% glutaralde-
hyde in 0.12M phosphate buffer. All samples were post-fixed with
1% OsO4 in cacodylate buffer, dehydrated in ethanol, and
embedded in epoxy resin. Ultrathin sections (60 nm), obtained with
an ultra microtome (Ultracut E; Reichert-Jung, Depew, NY), were
doubly stained with uranyl acetate and lead citrate and then
examined by transmission electron microscope CM 10 Philips (FEI,
Eindhoven, The Netherlands).
Statistical analyses
The differences in tumorigenicity (tumor take and latency) and in the
tumor mass of the xenografts generated by melanospheres and
adherent cells were statistically evaluated. For all the analyses,
multiple regression models were used: a log-normal model for
‘‘time-to-event’’ data to evaluate differences in the tumorigenicity,
and a generalized linear model for normal data in the case of tumor
mass. The statistical assumptions were verified, and the log-normal
model was chosen as being the best fit among a number of
parametric alternatives (exponential, Weibull, and log-logistic
models). The model predictors were treatment (melanospheres and
adherent melanoma cells), cell line (Me204, MeJR8, and Me14346),
and dose (104, 103, and 102). When treatment was the factor of
experimental interest, cell line and dose represented study design-
related covariates. All these factors were categorical, and thus coded
within the models by indicator (0–1) dummy variables. A search for
interactions between treatment and cell line or dose was also
performed. Analyses were performed with SAS (Cary, NC); two-sided
P-values of o0.05 were considered statistically significant. Row
outputs of the analyses are included in the Supplementary Material.
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